Introduction
Coronary artery disease (CAD) is a major global health concern responsible for an estimated 32% of deaths globally (Mortality and Causes of Death, 2015) . An important, but under-recognized determinant of outcomes in CAD is depression. Major depressive disorder (MDD) affects up to 20% of CAD patients (Huffman et al., 2013) with minor depression affecting an additional 30% to 45% of CAD patients (Frasure-Smith and Lesperance, 2006) . Both major and minor depressive symptoms are strong independent contributors to mortality in those with CAD (Barth et al., 2004) and interact negatively with psychosocial rehabilitation (Mayou et al., 1978) , adherence to cardiac medications (Blumenthal et al., 1982) , and overall quality of life (Ruo et al., 2003) .
Although secondary prevention programs such as cardiac rehabilitation (CR) improve cardiac outcomes and depressive symptoms in CAD patients (Milani and Lavie, 2007) , those with depressive symptoms have higher rates of CR non-adherence and associated mortality compared to those without (Swardfager et al., 2011) . These discrepancies present a clinical conundrum: depressive symptoms may prevent those with CAD from maximizing the benefits of CR. Current antidepressants are modestly effective in patients with mild to moderate depression.
Previous studies with selective serotonin reuptake inhibitors, the first-line pharmacotherapeutic agents, have reported remission rates of only 26-64%, suggesting the need for novel therapeutic interventions (Glassman et al., 2002; Honig et al., 2007; Lesperance et al., 2007; Strik et al., 2000) . As such, there is a need to explore mechanisms underlying depression in CAD, which may hinder the benefits of CR.
Contemporary evidence suggests that oxidative stress may be an important mechanism underlying depression in CAD. Briefly, normal cellular metabolism produces reactive oxygen A C C E P T E D M A N U S C R I P T 4 species (ROS), which are involved in signal transduction, gene expression and protein modification. However, when ROS generation overwhelms cellular antioxidant defence systems, oxidative stress occurs, damaging cellular components including DNA and lipid membranes.
Given that lipids are a central component of CAD pathology, oxidative damage to lipids or lipid peroxidation may have substantial clinical impact. In the early stages of lipid peroxidation, polyunsaturated fatty acids (PUFAs) react with hydroxyl radicals to produce lipid hydroperoxides (LPH), which can be neutralized by antioxidants. Subsequently, if LPH production exceeds antioxidant capacity, late-stage lipid peroxidation products such as 4-hydroxynonenal (4-HNE) and 8-isoprostane (8-ISO) are formed (Sultana et al., 2013) . These lipid peroxidation markers are elevated in CAD, as they are transported by low density lipoproteins to initiate proinflammatory processes, leading to the hallmark formation of atherosclerotic plaques (Singh and Jialal, 2006) . Cross-sectional studies have shown elevated markers of lipid peroxidation in both CAD (Kaur et al., 2008; Simon et al., 2013) and depression (Mazereeuw et al., 2015; Selley, 2004) . Moreover, improvements in cardiopulmonary fitness decrease lipid peroxidation and improve anti-oxidant levels (Pialoux et al., 2009 ). However, the relationship between lipid peroxidation and depression in CAD patients undertaking CR, a group in which this mechanism may be particularly relevant, remains unclear.
This study aimed to explore the longitudinal relationship between depressive symptoms and levels of lipid peroxidation markers in patients with CAD undertaking CR. Our primary hypothesis was that lipid peroxidation, as measured by the early stage marker (LPH) and late stage markers (4-HNE and 8-ISO), would decrease less in depressed CAD patients compared to non-depressed CAD patients during a 6-month CR program. We also hypothesized that these A C C E P T E D M A N U S C R I P T 5 changes in lipid peroxidation would be associated with changes in severity of depressive symptoms during the 6-month CR program.
Methods

Study Participants
The present study was approved by the research ethic boards at both the University Health Network (UHN) and Sunnybrook Health Sciences Centre. Written, informed consent was obtained before participants were assessed for inclusion/exclusion criteria. Participants were recruited at the beginning of a 6-month CR program at the UHN Toronto Rehabilitation Institute between May 2012 and June 2015. All included participants had evidence of CAD (previous hospitalization for acute myocardial infarction, prior revascularization procedure, or coronary angiographic evidence of ≥50% blockage in one or more major coronary artery), were aged 50-75 and could speak and understand English. All participants were being treated with a statin.
Participants were excluded if they were diagnosed with a significant acute medical illness, neurological condition, active cancer, surgery planned within the next year, schizophrenia, bipolar disorder, or cognitive impairment, as determined by a score of ≤24 on the standardized Mini-Mental State Examination (MMSE) (Molloy and Standish, 1997) .
Demographic and Clinical Characteristics
A comprehensive list of demographic and clinical characteristics was documented during participant interviews, corroborated by the electronic medical records at UHN. Specifically, a detailed medical history, concomitant medications and anthropometric variables (i.e. height, weight, body mass index and waist circumference) were recorded.
Cardiac Rehabilitation Program
A C C E P T E D M A N U S C R I P T 6 A detailed description of the CR program has been provided previously (Saleem et al., 2013) . Briefly, the CR program consists of weekly supervised sessions of aerobic exercise, either walking or jogging as clinically appropriate with additional at-home sessions 4 days per week.
Participants are also expected to complete resistance training exercises 1-2 times per week.
Cardiopulmonary fitness was assessed at baseline and 6 months using a cycle ergometer (Ergoselect 200p, Ergoline, Bitz, Germany) and expressed as peak volume of oxygen uptake (VO 2peak ). Participants were defined as a completer if they attended 80% or more of the weekly supervised sessions over the course of 6 months.
Depression Assessments
The Structured Clinical Interview for Depression (SCID) was used to diagnose depression at baseline. It was administered by a trained researcher under the supervision of the study psychiatrist to determine if participants met the Diagnostic and Statistical Manual, Version 4 (DSM-IV) criteria for minor depression or MDD. Diagnosis of minor depression was based on at least 2 weeks of depressive symptoms but with at least 2 but less than 5 additional symptoms required for MDD.
The Center for Epidemiological Studies Depression Scale (CES-D) was used to measure severity of depressive symptoms at both the baseline and 6-month visits. Briefly, the CES-D is a 20-item, self-report questionnaire with 4 options for each question for a maximum score of 60.
Measurement of Lipid Peroxidation Markers
Serum concentrations of LPH, 8-ISO and 4-HNE were measured as previously described (Andreazza et al., 2009; Scola et al., 2016) . Briefly, serum concentrations of LPH were measured based on absorbance relative to hydroperoxide at 500 nm using a colorimetric assay (Cayman Chemical, Michigan, USA). Intra-assay coefficient of variation (CV) ranged from 2 -15% and
inter-assay CV was 9%. An enzyme-linked immunosorbent assay (ELISA) (Cell Biolabs, Inc., San Diego, USA), which employed the use of a Michael Addition to lysine, histidine, or cysteine, was used to measure serum concentrations of 4-HNE. Intra-assay CV was 1-16% and inter-assay CV was 7.5%. Lastly, a standard competitive sandwich ELISA was used to measure serum concentrations of 8-ISO. The intra-assay CV was 1-19% and inter-assay CV was 9.1%.
Outcomes
The primary outcome was differences in change in lipid peroxidation markers (LPH, 4-HNE and 8-ISO) between depressed and non-depressed CAD patients over the course of 6 months of CR. The change in depressive symptom severity over 6 months was an exploratory outcome.
Statistical Analysis
All concentrations of lipid peroxidation markers were log-transformed before analysis to ensure a normal distribution. Univariate chi-squared tests and analysis of variance (ANOVA) were used to assess clinical and demographic differences between depressed (as assessed by SCID) and non-depressed CAD participants. Mixed models are able to model repeated measures data without omitting cases with missing values. Therefore, relationships between VO 2 peak , lipid peroxidation markers and CES-D scores over the course of CR using were assessed by bivariate mixed models. To test our primary hypothesis, multivariate mixed models were used to evaluate the differences in the trajectories of LPH, 4-HNE, and 8-ISO concentrations between depressed and non-depressed participants over 6 months of CR. Next, multivariate mixed models were used to evaluate the association between change in LPH, 4-HNE, and 8-ISO and change in CES-D score over 6 months of CR. All multivariate models included the following a priori covariates: age, gender, BMI, VO 2peak , history of depression, and completion of the prescribed CR program.
Mixed model analyses were conducted using the PROC MIXED protocol in SAS University Edition statistical software (SAS Institute Inc., North Carolina, USA), using a two-tailed significance level of p<0.05.
Sample Size
A repeated-measures analysis was proposed to assess differences in change lipid peroxidation markers LPH, 4-HNE and 8-ISO (dependents) between depressed and nondepressed CAD patient groups (independent) over 6 months with observations at baseline and 6 months. A sample size of 34 (17 per group) achieves 80% power for a repeated measure analysis of covariance with a two-sided α of 0.05 to detect a medium effect size for the primary hypothesis.
Results
Participant Characteristics
The study recruitment process is shown in Figure 1 . During the recruitment period, 1563 CAD patients entered the CR program. Of these, 933 patients had evidence of CAD. From the patients who agreed to participate and met inclusion criteria, 120 patients were included in the study and 18 patients met DSM-IV criteria for depression (6 MDD and 12 minor depression). Of the patients included in the study, 100 completed the 6-month CR program. LPH measurements were available in 86 participants and 8-ISO and 4-HNE measurements were available in 97 participants at 6-month follow-up. CES-D scores were available in all participants that completed the CR program.
Demographic and clinical characteristics of the study participants (n=120) are summarized ( Table 1) . As can be seen, the study population was predominantly male and Caucasian. Depressed CAD patients had a higher prevalence of a positive depression history and A C C E P T E D M A N U S C R I P T 9 a higher CES-D score compared to non-depressed CAD patients. Log-transformed serum concentrations of 4-HNE, but not LPH or 8-ISO were significantly higher in depressed CAD patients compared to non-depressed patients at baseline. No other clinical and demographical differences were found between the two groups.
Association between cardiopulmonary fitness, lipid peroxidation, and depressive symptoms
In unadjusted models, an increase in VO 2peak over CR was significantly associated with a decrease in 8-ISO (b=-0.007, p=0.028), but not LPH (b=0.009, p=0.11), 4-HNE (b=-0.0003, p=0.75) or CES-D scores (b=-1.10, p=0.13).
Change in lipid peroxidation markers between depressed and non-depressed CAD patients
Serum 4-HNE concentrations significantly increased in depressed CAD patients compared to non-depressed CAD patients after adjusting for age, gender, BMI, VO 2peak , history of depression, and CR completion status (Table 2) . Specifically, there was a 0.06 log unit increase in 4-HNE in the depressed CAD group. Conversely, there were no differences in change in LPH and 8-ISO over 6-months between depression diagnosis groups after adjusting for potential confounders.
Association between Lipid Peroxidation Markers and Severity of Depressive Symptoms over 6 Months
In the overall study population, a decrease in 4-HNE concentrations over 6 months was significantly associated with a decrease in CES-D scores adjusting for age, gender, BMI, VO 2peak , history of depression, and CR completion status (b=19.47, p<0.001). There were no associations between change in LPH or 8-ISO concentrations and change in depressive symptoms over 6 months (Table 3) .
Discussion
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This study assessed the relationships between depression and serum markers of lipid peroxidation over a 6-month CR program in participants with CAD. Over 6 months, those who were depressed had a significant increase in serum 4-HNE relative to those who were not depressed. Additionally, a decrease in serum 4-HNE in the overall study group was significantly associated with an improvement in depressive symptoms over the course of CR.
At baseline, depressed participants had significantly elevated 4-HNE levels compared to non-depressed participants, suggesting that depression in CAD may be associated with a prooxidative state. Longitudinally, there was a significant increase in 4-HNE in depressed CAD patients compared to non-depressed patients despite exercise. Additionally, a decrease in 4-HNE overall was associated with an improvement in depressive symptom severity over the course of 6 months. However, the same trend was not observed with LPH and 8-ISO levels. While previous cross-sectional studies report that levels of LPH and 8-ISO are elevated in depressed populations (Selley, 2004; Vargas et al., 2013) , the lack of association between LPH and depression may be due to depleted antioxidant defenses. Antioxidants such as glutathione (GSH) have been shown to be reduced in the brain of depressed patients compared to non-depressed controls in a postmortem study (Gawryluk et al., 2011) . GSH depletion may lead to a pro-oxidative state resulting in conversion of LPH to 8-ISO and 4-HNE and accumulation of these late-stage lipid peroxidation products. In addition, 8-ISO levels in the present study population may have been confounded by health and lifestyle factors (Black et al., 2016) and use of statins (Sinzinger and Oguogho, 2003) .
Several mechanisms link 4-HNE and depression. First, the high degree of 4-HNE cytotoxicity stems from its ability to react with various biomolecules including DNA, lipids, and proteins. In proteins, 4-HNE can form Michael adducts with amino acids, thus impairing the A C C E P T E D M A N U S C R I P T 11 function of proteins critical to mood regulation (Barrera et al., 2015) . For example, in a rat model of bipolar depression, 4-HNE formed adducts with vesicular monoamine transporter 2 (VMAT2), which is responsible for packaging monoamine neurotransmitters, including serotonin into synaptic vesicles (Tan et al., 2012) . Given that certain VMAT2 haplotypes have been previously associated with depressive symptoms (Christiansen et al., 2007) , the connection between 4-HNE and depressive symptoms may involve modulation of serotonin neurotransmission.
Another potential linkage between 4-HNE and depression involves the reduced bioavailability of the vasodilator, nitric oxide (NO), which plays an important role in both CAD and depression etiology (Sherwood et al., 2005) . In CAD, reduced NO levels result in impaired vasodilation, while its reduced bioavailability is suggested to alter neurotransmission involved in depression (Dhir and Kulkarni, 2011) . Specifically, evidence suggests that 4-HNE modulates NO levels through increasing levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. 4-HNE levels have been shown to positively correlate with levels of ADMA and negatively correlate with NO levels in depression (Selley, 2004) . Furthermore, 4-HNE can inhibit the activity of dimethylarginine dimethylaminohydrolase-1, an enzyme responsible for catabolizing ADMA (Forbes et al., 2008) .
Lastly, 4-HNE accumulation could elicit depressive symptoms through induction of apoptosis, leading to neuronal cell death (Kruman et al., 1997) . Depression is associated with decreased hippocampal volume and exhibits high comorbidity with neurodegenerative diseases (Hurley and Tizabi, 2013) . CAD subjects also have 13-15% reductions in hippocampal volume compared to healthy controls (Koschack and Irle, 2005) . Long-term exposure to increased A C C E P T E D M A N U S C R I P T 12 oxidative stress in CAD could result in accumulation of 4-HNE, leading to subsequent neurodegeneration and depression.
The biochemical mechanisms described outline an important potential role of 4-HNE in depression etiology, which may be particularly relevant in CAD patients, who likely have oxidative stress. As such, modulation of 4-HNE activity may hold important implications for future antidepressant development. For example, mitochondrial aldehyde dehydrogenase (ALDH2) plays a key role in detoxification of aldehydes produced during oxidative stress. A recent study in a rat model of depression showed that administration of ALDH2 activator 1, 3-benzodioxol-5-ylmethyl-2-6-dichlorobenzamide decreased both depressive-like behaviours and plasma levels of 4-HNE adducts (Stachowicz et al., 2016) .
While a decrease in oxidative stress markers has been previously reported during CR programs (Fukuda et al., 2013) , the decrease in 4-HNE was not associated with cardiopulmonary fitness in this study. This may be due to several reasons. First, the CR program at UHN Toronto Rehabilitation consisted of both aerobic exercise and resistance training, which is consistently associated with reduced oxidative stress (Cakir-Atabek et al., 2010) . However, resistance training could not be assessed as a predictor of change in oxidative stress markers due to the lack of documentation. Healthy dietary changes were also encouraged during the CR program and may have contributed to the decrease in lipid peroxidation markers. For example, high antioxidant diets such as the traditional Mediterranean diet have previously been shown to reduce plasma oxidative stress markers (Fito et al., 2007) . Moreover, cardiovascular medications like statins may also have antioxidant properties (Kruman et al., 1997) . Thus, differences in medications and dosing may also confound the relationship between cardiopulmonary fitness and oxidative stress in the present study. This study was limited by the small sample size of depressed patients compared to the non-depressed group. However, the proportion of patients who met criteria for MDD in the present study is representative of the prevalence of depression in CAD patients (Huffman et al., 2013) . Another limitation of this study was that it assessed peripheral markers as indicators of brain physiology. However, it has been shown previously that peripheral lipid peroxidation markers correlate with neuropathy in psychiatric disorders (Versace et al., 2014) . In addition, we have previously shown associations between peripheral oxidative stress markers and antidepressant response in patients with CAD (Mazereeuw et al., 2017) , further validating peripheral markers of lipid peroxidation as predictors of depression outcomes.
In summary, we showed that in a sample of patients with CAD, 4-HNE was increased significantly in those who were depressed compared to those who were not. Additionally, a decrease in 4-HNE was correlated with a decrease in depressive symptoms over a 6-month period of CR. These findings suggest 4-HNE may be an important marker of depressive symptoms in CAD and suggest a specific role of 4-HNE in the development and progression of A C C E P T E D M A N U S C R I P T 21   Table 3 Association between change in lipid peroxidation markers and change in CES-D score over 6 months. 
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